Schering patent expiration

1. Noxafil patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5703079 SCHERING Tetrahydrofuran antifungals
Aug, 2014

(9 years ago)

US6958337 SCHERING Crystalline antifungal polymorph
Oct, 2018

(5 years ago)

US5661151 SCHERING Tetrahydrofuran antifungals
Jul, 2019

(4 years ago)

US8263600 SCHERING Antifungal composition with enhanced bioavailability
Apr, 2022

(2 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2011

Drugs and Companies using POSACONAZOLE ingredient

NCE-1 date: 15 September, 2010

Market Authorisation Date: 15 September, 2006

Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis

Dosage: SUSPENSION

How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage

NOXAFIL family patents

Family Patents

2. Rebetol patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6461605 SCHERING Continuous low-dose cytokine infusion therapy
Nov, 2016

(7 years ago)

US6177074 SCHERING Polyethylene glycol modified interferon therapy
Nov, 2016

(7 years ago)

US6524570 SCHERING Polyethylene glycol modified interferon therapy
Nov, 2016

(7 years ago)

US6177074

(Pediatric)

SCHERING Polyethylene glycol modified interferon therapy
May, 2017

(7 years ago)

US6524570

(Pediatric)

SCHERING Polyethylene glycol modified interferon therapy
May, 2017

(7 years ago)

US6461605

(Pediatric)

SCHERING Continuous low-dose cytokine infusion therapy
May, 2017

(7 years ago)

US6172046 SCHERING Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Sep, 2017

(6 years ago)

US6472373 SCHERING Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Sep, 2017

(6 years ago)

US6172046

(Pediatric)

SCHERING Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
Mar, 2018

(6 years ago)

US6472373

(Pediatric)

SCHERING Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
Mar, 2018

(6 years ago)

US6790837 SCHERING Ribavirin syrup formulations
Apr, 2023

(1 year, 3 months ago)

US6790837

(Pediatric)

SCHERING Ribavirin syrup formulations
Oct, 2023

(9 months ago)




Drugs and Companies using RIBAVIRIN ingredient

Market Authorisation Date: 29 July, 2003

Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...

Dosage: SOLUTION

How can I launch a generic of REBETOL before it's drug patent expiration?
More Information on Dosage

REBETOL family patents

Family Patents